Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.

In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease c...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, H. J., Forrest, A. P., Everington, D., McDonald, C. C., Dewar, J. A., Hawkins, R. A., Prescott, R. J., George, W. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074573/
https://www.ncbi.nlm.nih.gov/pubmed/8688340
_version_ 1782137995824988160
author Stewart, H. J.
Forrest, A. P.
Everington, D.
McDonald, C. C.
Dewar, J. A.
Hawkins, R. A.
Prescott, R. J.
George, W. D.
author_facet Stewart, H. J.
Forrest, A. P.
Everington, D.
McDonald, C. C.
Dewar, J. A.
Hawkins, R. A.
Prescott, R. J.
George, W. D.
author_sort Stewart, H. J.
collection PubMed
description In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease control from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death without relapse) is 1.27, 95% CI = 0.87 - 1.85.] There is a suggestion that therapy for longer than 5 years may increase the risk of endometrial carcinoma (P = 0.064).
format Text
id pubmed-2074573
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20745732009-09-10 Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Stewart, H. J. Forrest, A. P. Everington, D. McDonald, C. C. Dewar, J. A. Hawkins, R. A. Prescott, R. J. George, W. D. Br J Cancer Research Article In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease control from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death without relapse) is 1.27, 95% CI = 0.87 - 1.85.] There is a suggestion that therapy for longer than 5 years may increase the risk of endometrial carcinoma (P = 0.064). Nature Publishing Group 1996-07 /pmc/articles/PMC2074573/ /pubmed/8688340 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Stewart, H. J.
Forrest, A. P.
Everington, D.
McDonald, C. C.
Dewar, J. A.
Hawkins, R. A.
Prescott, R. J.
George, W. D.
Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.
title Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.
title_full Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.
title_fullStr Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.
title_full_unstemmed Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.
title_short Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.
title_sort randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. the scottish cancer trials breast group.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074573/
https://www.ncbi.nlm.nih.gov/pubmed/8688340
work_keys_str_mv AT stewarthj randomisedcomparisonof5yearsofadjuvanttamoxifenwithcontinuoustherapyforoperablebreastcancerthescottishcancertrialsbreastgroup
AT forrestap randomisedcomparisonof5yearsofadjuvanttamoxifenwithcontinuoustherapyforoperablebreastcancerthescottishcancertrialsbreastgroup
AT everingtond randomisedcomparisonof5yearsofadjuvanttamoxifenwithcontinuoustherapyforoperablebreastcancerthescottishcancertrialsbreastgroup
AT mcdonaldcc randomisedcomparisonof5yearsofadjuvanttamoxifenwithcontinuoustherapyforoperablebreastcancerthescottishcancertrialsbreastgroup
AT dewarja randomisedcomparisonof5yearsofadjuvanttamoxifenwithcontinuoustherapyforoperablebreastcancerthescottishcancertrialsbreastgroup
AT hawkinsra randomisedcomparisonof5yearsofadjuvanttamoxifenwithcontinuoustherapyforoperablebreastcancerthescottishcancertrialsbreastgroup
AT prescottrj randomisedcomparisonof5yearsofadjuvanttamoxifenwithcontinuoustherapyforoperablebreastcancerthescottishcancertrialsbreastgroup
AT georgewd randomisedcomparisonof5yearsofadjuvanttamoxifenwithcontinuoustherapyforoperablebreastcancerthescottishcancertrialsbreastgroup

Ejemplares similares